BTK and acute myeloid leukemia: Figure 2B shows that ibrutinib inhibits SDF1 induced BTK, MAPK and AKT phosphorylation in AML at concentrations equivalent to those that can be achieved in vivo (based on ibrutinib 420 mg orally once a day) [10, 16].